Author contributions ZJ, TI, and HN designed research, performed experiments, analyzed data, and wrote the manuscript
doi: 10.1007/s13555-018-0278-6
There are a few conditions that may prevent you from receiving treatment
Eligibility for the Medicare GLP-1 Bridge will also be limited to Medicare beneficiaries who have not filled a prescription under their Part D plan for a GLP-1 in 2026, and who do not have a diagnosis with a condition that is a medically accepted indication for a GLP-1 drug that could be covered under Part D (specified by CMS as type 2 diabetes, obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)), even if they otherwise meet the clinical criteria
Some medications such as anticonvulsants and proton pump inhibitors, can also increase the likelihood of B12 deficiency through varied mechanisms
Many patients do well long-term at 5 to 10 mg tirzepatide or 1.0 to 1.7 mg semaglutide